EuroThrombosis & EuroVessels 2022
20-22 October | SANA LISBOA
Lisbon, Portugal

Preliminary programme

www.etev2022.com
Thursday, 20 October

14:00 - 14:25  
ROOM A/B | **Opening lecture**  
- AHEROTHROMBOSIS: a contemporary overview a glimpse into the future

14:30 - 16:00  
ROOM A | **New avenues for combating atherothrombosis**  
- The era of personalized medicine on antithrombotics  
- Ongoing preclinical and clinical trials on FXIa and FXIIa  
- New developments in P2Y12 blockade  
- Repurposing old drugs targeting inflammation

ROOM B | **New avenues for combating venous thromboembolism**  
- Pulmonary embolism: for whom revascularization is an option?  
- Deep vein thrombosis: for whom revascularization is an option?  
- Personalized treatment of VTE in non cancer patients  
- Personalized treatment of VTE in cancer patients

16:00 - 16:30 | Posters & coffee break

16:30 - 17:55  
ROOM A | **Challenges in antithrombotic therapy in special populations**  
- Cardiogenic shock  
- Polyvascular atherosclerotic disease  
- The elderly and the very elderly  
- Chronic kidney disease

ROOM B | **Coronary Microcirculatory Dysfunction**  
Joint Session with the ESC WG on Coronary Pathophysiology & Microcirculation  
- Role of coronary microvascular dysfunction in cardiovascular disease  
- Ischemic heart disease in women: Risk Factors and Pathophysiology  
- How to address the no-reflow phenomenon in ACS  
- The role of peripheral vein microcirculation on adverse clinical outcomes

18:00 - 18:25  
ROOM A/B | **Fontaine Lecture**  
- Global Burden PAD

18:30 - 19:15  
ROOM A | **Industry Satellite Symposium I**  
ROOM B | **Industry Satellite Symposium II**
Friday, 21 October

08:00 - 08:55
ROOM A | Case-based session
Organised by the ESC WG on Thrombosis Young Researchers

09:00 - 10:30
ROOM A | Unreveling the complexity of thrombosis in ACS
- Cardiac benefits of P2Y12 inhibitors beyond their antiplatelet properties
- Monocyte and macrophage subsets in coronary artery disease and beyond
- Epigenetics in atherothrombosis
- Factor Xa and platelet activation

ROOM B | Understanding Fybromuscular Dysplasia (FMD)
- Understanding and phenotyping FMD in 2022
- OMICS in FMD
- Treating FMD and beyond
- FMD in coronary arteries (imaging and management)

10:30 - 11:00 | Posters & coffee break

11:00 - 12:25
ROOM A | Diabetes: targeting the increase in cardiovascular risk
- Managing lipids: does LDL still matter?
- Managing glucose metabolism: does glycemia still matter?
- How to stratify risk in diabetic patients
- Platelet inhibition

ROOM B | Lower Extremity Artery Disease: improved management for better outcome
- Optimal pharmacotherapy
- Best Exercise training modalities
- Endovascular revascularization? What we know and where we are heading to
- Biomarkers in LEAD

12:30 - 13:15
ROOM A | Lunch & Industry Satellite Symposium III
ROOM B | Lunch & Industry Satellite Symposium IV

13:20 - 14:05
ROOM A | Lunch & Industry Satellite Symposium V
ROOM B | Lunch & Industry Satellite Symposium VI
14:10 - 15:40
ROOM A | **Antithrombotics in non coronary interventions**
- TAVI
- Left Atrial Appendage and PFO
- Peripheral revascularization
- Aortic endovascular therapy

ROOM B | **Platelets in atherosclerosis and vascular biology: beyond thrombosis**
Joint Session with the ESC WG on Atherosclerosis and Vascular Biology
- Platelet-derived extracellular vesicles, chemokines and cell adhesion molecules in atherosclerosis
- Platelet-derived EVs as biological players after myocardial infarction – good or bad?
- Platelets in vascular and valvular calcification
- Vascular injury and repair and the journey of microthrombi following mechanical thrombectomy

15:40 - 16:00 | Posters & coffee break

16:00 - 17:25
ROOM A | **Novel approaches in Lower Extremity Artery Disease (LEAD)**
Joint Session with the European Society of Vascular Medicine
- Supervised exercise training in LEAD: alternative or adjuvant to revascularization?
- Interventional management of calcified arterial lesions
- Regenerative therapy in no-option chronic limb threatening ischemia
- Air pollution and Critical Limb Ischemia

ROOM B | **Prevention strategies in the continuum of CV risk**
- Effects of exercise training on atherothrombotic risk
- The polypill in primary and secondary prevention. Where do we stand?
- Preventive strategies in patients with CKD
- Association between influenza vaccination and cardiovascular diseases

17:30 - 17:55
ROOM A | **Steen Husted Lecture**
- Current advances in ischemic stroke research and therapies

18:00 - 18:30
ROOM A | **ESC WG on Thrombosis General Assembly**
Saturday, 22 October

- General information to members of the Working Group (ongoing and upcoming activities)

08:00 - 08:55
ROOM A | Moderated posters
ROOM B | Case-based session
Organised by the ESC WG on Aorta and Peripheral Diseases

09:00 - 10:30
ROOM A | Update on antithrombotic strategies
- Novel DAPT strategies for individualized treatment of CAD patients: Phenotyping & Genotyping approaches
- Antithrombotic strategies after AMI
- Dual pathway in atherothrombotic disorders
- Atrial fibrillation
ROOM B | Aorta - What’s new since the 2014 guidelines?
- Genetics of Aortic Diseases
- New multimodality imaging techniques of the thoracic and abdominal aorta
- Type B aortic dissection: when to intervene
- Ruptured AAA: from prevention to intervention

10:30 - 11:00 | Posters & coffee break

11:00 - 12:25
ROOM A | Optimizing outcomes in Vascular Surgery
Joint Session with the European Society of Vascular Surgery
- Should we continue to screen cardiac diseases prior to peripheral revascularization?
- Optimal medical treatment of candidates to Vascular Surgery in 2022
- Peri-operative management of antithrombotic therapies
- Follow-up after vascular intervention
ROOM B | Predictive Biomarkers
- Biomarkers of bleeding
- Biomarkers of arterial thrombosis
- Biomarkers of fibrinolysis
- Biomarkers of venous thrombosis

12:30 - 13:00 | Poster awards and closure of conference